Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
  • C07C215/68—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
  • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
• • C—CHEMISTRY; METALLURGY
  • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
  • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
  • C09B69/00—Dyes not provided for by a single group of this subclass
  • C09B69/10—Polymeric dyes; Reaction products of dyes with monomers or with macromolecular compounds
  • C09B69/101—Polymeric dyes; Reaction products of dyes with monomers or with macromolecular compounds containing an anthracene dye
  • C09B69/102—Polymeric dyes; Reaction products of dyes with monomers or with macromolecular compounds containing an anthracene dye containing a perylene dye
• • C—CHEMISTRY; METALLURGY
  • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
  • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
  • C09B69/00—Dyes not provided for by a single group of this subclass
  • C09B69/10—Polymeric dyes; Reaction products of dyes with monomers or with macromolecular compounds
  • C09B69/103—Polymeric dyes; Reaction products of dyes with monomers or with macromolecular compounds containing a diaryl- or triarylmethane dye
• • C—CHEMISTRY; METALLURGY
  • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
  • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
  • C09B69/00—Dyes not provided for by a single group of this subclass
  • C09B69/10—Polymeric dyes; Reaction products of dyes with monomers or with macromolecular compounds
  • C09B69/109—Polymeric dyes; Reaction products of dyes with monomers or with macromolecular compounds containing other specific dyes
• • C—CHEMISTRY; METALLURGY
  • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
  • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
  • C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
  • C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N1/00—Sampling; Preparing specimens for investigation
  • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
  • G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
  • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
  • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
  • G01N21/64—Fluorescence; Phosphorescence
  • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
  • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
  • G01N33/583—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with non-fluorescent dye label
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
  • G01N15/10—Investigating individual particles
  • G01N2015/1006—Investigating individual particles for cytology

Definitions

• the present invention is generally directed to dimeric and polymeric fluorescent or colored dyes having rigid spacing groups, and methods for their preparation and use in various analytical methods.
• Fluorescent and/or colored dyes are known to be particularly suitable for applications in which a highly sensitive detection reagent is desirable. Dyes that are able to preferentially label a specific ingredient or component in a sample enable the researcher to determine the presence, quantity and/or location of that specific ingredient or component. In addition, specific systems can be monitored with respect to their spatial and temporal distribution in diverse environments.
• Fluorescence and colorimetric methods are extremely widespread in chemistry and biology. These methods give useful information on the presence, structure, distance, orientation, complexation and/or location for biomolecules.
• time-resolved methods are increasingly used in measurements of dynamics and kinetics.
• many strategies for fluorescence or color labeling of biomolecules, such as nucleic acids and protein have been developed. Since analysis of biomolecules typically occurs in an aqueous environment, the focus has been on development and use of water soluble dyes.
• embodiments of the present invention are generally directed to compounds useful as water soluble, fluorescent and/or colored dyes and/or probes that enable visual detection of analyte molecules, such as biomolecules, as well as reagents for their preparation. Methods for visually detecting analyte molecules using the dyes are also described.
• Embodiments of the presently disclosed dyes include two or more fluorescent and/or colored moieties covalently linked by a rigid linker ("A").
• A rigid linker
• the present dyes are significantly brighter than the corresponding monomelic dye compound. While, not wishing to be bound by theory, it is believed that the rigid linker moiety provides sufficient spatial separation between the fluorescent and/or colored moieties such that intramolecular fluorescence quenching is reduced and/or eliminated.
• the water soluble, fluorescent or colored dyes of embodiments of the invention are intensely colored and/or fluorescent and can be readily observed by visual inspection or other means. In some embodiments the compounds may be observed without prior illumination or chemical or enzymatic activation. By appropriate selection of the dye, as described herein, visually detectable analyte molecules of a variety of colors may be obtained.
• a method for staining a sample comprises adding to said sample a compound of structure (I) in an amount sufficient to produce an optical response when said sample is illuminated at an appropriate wavelength.
• the present disclosure provides a method for visually detecting an analyte molecule, comprising:
• Other disclosed methods include a method for visually detecting a biomolecule, the method comprising:
• compositions comprising a compound of structure (I) and one or more biomolecules. Use of such compositions in analytical methods for detection of the one or more biomolecules is also provided.
• a method for labeling an analyte molecule comprising:
• step (b) reacting the product of step (A) with the analyte molecule, thereby forming a conjugate of the product of step (A) and the analyte molecule wherein R 2 , R 3 , Q, G and M-L lb -G' are as defined herein.
• Figure 1 provides UV absorbance spectra for comparative dye compounds.
• Figure 2 provides fluorescence emmision spectra for comparative dye compounds.
• Carboxy refers to the -C0 2 H group.
• Cyano refers to the -CN group.
• Niro refers to the -N0 2 group.
• Alkyl refers to a straight or branched hydrocarbon chain group consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to twelve carbon atoms (Ci-Ci 2 alkyl), one to eight carbon atoms (Ci-C 8 alkyl) or one to six carbon atoms (Ci-C 6 alkyl), and which is attached to the rest of the molecule by a single bond, e.g., methyl, ethyl, ⁇ -propyl, 1-methylethyl (z ' so-propyl), «-butyl, «-pentyl, 1, 1-dimethylethyl (t-butyl), 3-methylhexyl, 2-methylhexyl, and the like. Unless stated otherwise specifically in the specification, alkyl groups are optionally substituted.
• Alkylene or "alkylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing no unsaturation, and having from one to twelve carbon atoms, e.g., methylene, ethylene, propylene, «-butylene, ethenylene, propenylene, «-butenylene, propynylene, «-butynylene, and the like.
• the alkylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond.
• the points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, alkylene is optionally substituted.
• alkenylene or “alkenylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing at least one carbon-carbon double bond and having from two to twelve carbon atoms, e.g., ethenylene, propenylene, «-butenylene, and the like.
• the alkenylene chain is attached to the rest of the molecule through a single bond and to the radical group through a double bond or a single bond.
• the points of attachment of the alkenylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, alkenylene is optionally substituted.
• Alkynylene or “alkynylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing at least one carbon-carbon triple bond and having from two to twelve carbon atoms, e.g., ethenylene, propenylene,
• alkynylene chain is attached to the rest of the molecule through a single bond and to the radical group through a double bond or a single bond.
• the points of attachment of the alkynylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, alkynylene is optionally substituted.
• Alkylether refers to any alkyl group as defined above, wherein at least one carbon-carbon bond is replaced with a carbon-oxygen bond.
• the carbon-oxygen bond may be on the terminal end (as in an alkoxy group) or the carbon oxygen bond may be internal (i.e., C-O-C).
• Alkylethers include at least one carbon oxygen bond, but may include more than one.
• polyethylene glycol (PEG) is included within the meaning of alkylether.
• an alkylether group is optionally substituted.
• Alkoxy refers to a group of the formula -OR a where R a is an alkyl group as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, an alkoxy group is optionally substituted.
• Heteroalkylene refers to an alkylene group, as defined above, comprising at least one heteroatom (e.g., N, O, P or S) within the alkylene chain or at a terminus of the alkylene chain.
• the heteroatom is within the alkylene chain (i.e., the heteroalkylene comprises at least one carbon-heteroatom- carbon bond).
• the heteroatom is at a terminus of the alkylene and thus serves to join the alkylene to the remainder of the molecule (e.g., M1-H-B-M2, where Ml and M2 are portions of the molecule, H is a heteroatom and B is an alkylene).
• a heteroalkylene group is optionally substituted.
• An exemplary heteroalkylene linking group is illustrated below:
• Multimers of the above C-linker are included in various embodiments of heteroalkylene linkers.
• Heteroalkenylene is a heteroalkylene, as defined above, comprising at least one carbon-carbon double bond. Unless stated otherwise specifically in the specification, a heteroalkenylene group is optionally substituted.
• Heteroalkynylene is a heteroalkylene comprising at least one carbon- carbon triple bond. Unless stated otherwise specifically in the specification, a heteroalkynylene group is optionally substituted.
• Heteroatomic in reference to a “heteroatomic linker” refers to a linker group consisting of one or more heteroatom.
• R b is -Oalkyl, wherein R c is a counter ion (e.g., Na+ and the like).
• a phosphoalkyl group is optionally substituted.
• the -Oalkyl moiety in a phosphoalkyl group is optionally substituted with one or more of hydroxyl, amino, sulfhydryl, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl,
• R b is OH, O " , S “ , OR d or SR d ; and R c is OH, SH, O “ , S “ , OR d , SR d , a phosphate group or a further thiophosphate group, wherein R d is a counter ion (e.g., Na+ and the like) and provided that: i) R a is S; ii) R b is S “ or SR d ; iii)Rc is SH, S “ or SR d ; or iv) a combination of i), ii) and/or iii).
• R d is a counter ion (e.g., Na+ and the like) and provided that: i) R a is S; ii) R b is S “ or SR d ; iii)Rc is SH, S " or SR d ; or iv) a combination of i),
• R b is OH, O " , S “ , OR d or SR d ; and Rc is -Oalkyl, wherein R d is a counter ion (e.g., Na+ and the like) and provided that: i) R a is S; ii) R b is S “ or SR d ; or iii)R a is S and R b is S " or SR d .
• R d is a counter ion (e.g., Na+ and the like) and provided that: i) R a is S; ii) R b is S " or SR d ; or iii)R a is S and R b is S " or SR d .
• thiophosphoalkyl group is optionally substituted.
• the -Oalkyl moiety in a thiophosphoalkyl group is optionally substituted with one or more of hydroxyl, amino, sulfhydryl, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkylether or thiophosphoalkylether.
• the -Oalkylether moiety in a thiophosphoalkyl group is optionally substituted with one or more of hydroxyl, amino, sulfhydryl, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkylether or thiophosphoalkylether.
• Carbocyclic refers to a stable 3- to 18-membered aromatic or non-aromatic ring comprising 3 to 18 carbon atoms.
• a carbocyclic ring may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems, and may be partially or fully saturated.
• Non-aromatic carbocyclyl radicals include cycloalkyl, while aromatic carbocyclyl radicals include aryl.
• a carbocyclic group is optionally substituted.
• Cycloalkyl refers to a stable non-aromatic monocyclic or polycyclic carbocyclic ring, which may include fused or bridged ring systems, having from three to fifteen carbon atoms, preferably having from three to ten carbon atoms, and which is saturated or unsaturated and attached to the rest of the molecule by a single bond.
• Monocyclic cyclocalkyls include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptly, and cyclooctyl.
• Polycyclic cycloalkyls include, for example, adamantyl, norbornyl, decalinyl, 7,7-dimethyl-bicyclo-[2.2.1]heptanyl, and the like. Unless stated otherwise specifically in the specification, a cycloalkyl group is optionally substituted.
• Aryl refers to a ring system comprising at least one carbocyclic aromatic ring. In some embodiments, an aryl cromprises from 6 to 18 carbon atoms.
• the aryl ring may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems.
• Aryls include, but are not limited to, aryls derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene. Unless stated otherwise specifically in the specification, an aryl group is optionally substituted.
• Heterocyclic refers to a stable 3- to 18-membered aromatic or non-aromatic ring comprising one to twelve carbon atoms and from one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur.
• the heterocyclic ring may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclic ring may be optionally oxidized; the nitrogen atom may be optionally quaternized; and the heterocyclic ring may be partially or fully saturated.
• heteroaryls examples include, but are not limited to, dioxolanyl, thienyl[l,3]dithianyl, decahydroisoquinolyl, imidazolinyl,
• Heteroaryl refers to a 5- to 14-membered ring system comprising one to thirteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and at least one aromatic ring.
• the heteroaryl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl radical may be optionally oxidized; the nitrogen atom may be optionally quatemized.
• Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzthiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[£][l,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotriazolyl,
• Fused refers to a ring system comprising at least two rings, wherein the two rings share at least one common ring atom, for example two common ring atoms.
• the fused ring is a heterocyclyl ring or a heteroaryl ring
• the common ring atom(s) may be carbon or nitrogen.
• Fused rings include bicyclic, tricyclic, tertracyclic, and the like.
• substituted used herein means any of the above groups (e.g., alkyl, alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene,
• heteroalkynylene alkoxy, alkylether, phosphoalkyl, phosphoalkylether,
• Substituted also means any of the above groups in which one or more hydrogen atoms are replaced by a higher-order bond (e.g., a double- or triple-bond) to a heteroatom such as oxygen in oxo, carbonyl, carboxyl, and ester groups; and nitrogen in groups such as imines, oximes, hydrazones, and nitriles.
• a higher-order bond e.g., a double- or triple-bond
• nitrogen in groups such as imines, oximes, hydrazones, and nitriles.
• R g and R h are the same or different and independently hydrogen, alkyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, N- heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl.
• Substituted further means any of the above groups in which one or more hydrogen atoms are replaced by a bond to an amino, cyano, hydroxyl, imino, nitro, oxo, thioxo, halo, alkyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl group.
• each of the foregoing substituents may also be optionally substituted with one or more of the above substituents.
• Conjugation refers to the overlap of one p-orbital with another p- orbital across an intervening sigma bond. Conjugation may occur in cyclic or acyclic compounds.
• a “degree of conjugation” refers to the overlap of at least one p-orbital with another p-orbital across an intervening sigma bond. For example, 1, 3-butadine has one degree of conjugation, while benzene and other aromatic compounds typically have multiple degrees of conjugation. Fluorescent and colored compounds typically comprise at least one degree of conjugation.
• Fluorescent refers to a molecule which is capable of absorbing light of a particular frequency and emitting light of a different frequency. Fluorescence is well- known to those of ordinary skill in the art.
• Cold refers to a molecule which absorbs light within the colored spectrum (i.e., red, yellow, blue and the like).
• a “linker” refers to a contiguous chain of at least one atom, such as carbon, oxygen, nitrogen, sulfur, phosphorous and combinations thereof, which connects a portion of a molecule to another portion of the same molecule or to a different molecule, moiety or solid support (e.g., microparticle). Linkers may connect the molecule via a covalent bond or other means, such as ionic or hydrogen bond interactions.
• biomolecule refers to any of a variety of biological materials, including nucleic acids, carbohydrates, amino acids, polypeptides, glycoproteins, hormones, aptamers and mixtures thereof. More specifically, the term is intended to include, without limitation, RNA, DNA, oligonucleotides, modified or derivatized nucleotides, enzymes, receptors, prions, receptor ligands (including hormones), antibodies, antigens, and toxins, as well as bacteria, viruses, blood cells, and tissue cells.
• the visually detectable biomolecules of the invention are prepared, as further described herein, by contacting a biomolecule with a compound having a reactive group that enables attachment of the biomolecule to the compound via any available atom or functional group, such as an amino, hydroxy, carboxyl, or sulfhydryl group on the biomolecule.
• a “reactive group” is a moiety capable of reacting with a second reactive groups (e.g., a “complementary reactive group”) to form one or more covalent bonds, for example by a displacement, oxidation, reduction, addition or cycloaddition reaction.
• Exemplary reactive groups are provided in Table 1, and include for example, nucleophiles, electrophiles, dienes, dienophiles, aldehyde, oxime, hydrazone, alkyne, amine, azide, acylazide, acylhalide, nitrile, nitrone, sulfhydryl, disulfide, sulfonyl halide, isothiocyanate, imidoester, activated ester, ketone, ⁇ , ⁇ -unsaturated carbonyl, alkene, maleimide, a-haloimide, epoxide, aziridine, tetrazine, tetrazole, phosphine, biotin, thiirane and the like.
• visible and “visually detectable” are used herein to refer to substances that are observable by visual inspection, without prior illumination, or chemical or enzymatic activation. Such visually detectable substances absorb and emit light in a region of the spectrum ranging from about 300 to about 900 nm. Preferably, such substances are intensely colored, preferably having a molar extinction coefficient of at least about 40,000, more preferably at least about 50,000, still more preferably at least about 60,000, yet still more preferably at least about 70,000, and most preferably at least about 80,000 M ⁇ cm "1 .
• the compounds of the invention may be detected by observation with the naked eye, or with the aid of an optically based detection device, including, without limitation, absorption spectrophotometers, transmission light microscopes, digital cameras and scanners.
• Visually detectable substances are not limited to those which emit and/or absorb light in the visible spectrum. Substances which emit and/or absorb light in the ultraviolet (UV) region (about 10 nm to about 400 nm), infrared (IR) region (about 700 nm to about 1 mm), and substances emitting and/or absorbing in other regions of the electromagnetic spectrum are also included with the scope of "visually detectable" substances.
• UV ultraviolet
• IR infrared
• the term "photostable visible dye” refers to a chemical moiety that is visually detectable, as defined hereinabove, and is not significantly altered or decomposed upon exposure to light.
• the photostable visible dye does not exhibit significant bleaching or decomposition after being exposed to light for at least one hour. More preferably, the visible dye is stable after exposure to light for at least 12 hours, still more preferably at least 24 hours, still yet more preferably at least one week, and most preferably at least one month.
• Nonlimiting examples of photostable visible dyes suitable for use in the compounds and methods of the invention include azo dyes, thioindigo dyes,
• quinacridone pigments dioxazine, phthalocyanine, perinone, diketopyrrolopyrrole, quinophthalone, and truarycarbonium.
• perylene derivative is intended to include any substituted perylene that is visually detectable. However, the term is not intended to include perylene itself.
• anthracene derivative e.g., perylene, pyrene, anthracene or naphthalene derivative
• a derivative is an imide, bisimide or hydrazamimide derivative of perylene, anthracene, naphthalene, or pyrene.
• the visually detectable molecules of various embodiments of the invention are useful for a wide variety of analytical applications, such as biochemical and biomedical applications, in which there is a need to determine the presence, location, or quantity of a particular analyte (e.g., biomolecule).
• the invention provides a method for visually detecting a biomolecule, comprising: (a) providing a biological system with a visually detectable biomolecule comprising the compound of structure (I) linked to a biomolecule; and (b) detecting the biomolecule by its visible properties.
• the phrase "detecting the biomolecule by its visible properties” means that the biomolecule, without illumination or chemical or enzymatic activation, is observed with the naked eye, or with the aid of a optically based detection device, including, without limitation, absorption spectrophotometers, transmission light microscopes, digital cameras and scanners.
• a densitometer may be used to quantify the amount of visually detectable biomolecule present.
• the relative quantity of the biomolecule in two samples can be determined by measuring relative optical density. If the stoichiometry of dye molecules per biomolecule is known, and the extinction coefficient of the dye molecule is known, then the absolute concentration of the biomolecule can also be determined from a measurement of optical density.
• biological system is used to refer to any solution or mixture comprising one or more biomolecules in addition to the visually detectable biomolecule.
• biological systems include cells, cell extracts, tissue samples, electrophoretic gels, assay mixtures, and hybridization reaction mixtures.
• Solid support refers to any solid substrate known in the art for solid- phase support of molecules
• a microparticle refers to any of a number of small particles useful for attachment to compounds of the invention, including, but not limited to, glass beads, magnetic beads, polymeric beads, nonpolymeric beads, and the like.
• a microparticle comprises polystyrene beads.
• Base pairing moiety refers to a heterocyclic moiety capable of hybridizing with a complementary heterocyclic moiety via hydrogen bonds (e.g., Watson-Crick base pairing).
• Base pairing moieties include natural and unnatural bases.
• Non-limiting examples of base pairing moieties are RNA and DNA bases such adenosine, guanosine, thymidine, cytosine and uridine and analogues thereof.
• Embodiments of the invention disclosed herein are also meant to encompass all compounds of structure (I) or (II) being isotopically-labelled by having one or more atoms replaced by an atom having a different atomic mass or mass number.
• isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as 2 H, 3 H, U C, 13 C, 14 C, 13 N, 15 N, 15 0, 17 0, 18 0, 31 P, 32 P, 35 S, 18 F, 36 C1, 123 I, and 125 I, respectively.
• Isotopically-labeled compounds of structure (I) or (II) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described below and in the following Examples using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
• Solid compound and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
• Salt includes both acid and base addition salts.
• Acid addition salt refers to those salts which are formed with inorganic acids such as, but not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid, camphor- 10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- 1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic
• naphthalene-l,5-disulfonic acid naphthalene-2-sulfonic acid, l-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic acid, pyroglutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanic acid, ⁇ -toluenesulfonic acid, trifluoroacetic acid, undecylenic acid, and the like.
• Base addition salt refers to those salts which are prepared from addition of an inorganic base or an organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like.
• Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, deanol, 2-dimethylaminoethanol, 2-diethylaminoethanol,
• dicyclohexylamine lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, benethamine, benzathine, ethylenediamine, glucosamine, methylglucamine, theobromine, tri ethanolamine, tromethamine, purines, piperazine, piperidine,
• N-ethylpiperidine polyamine resins and the like.
• Particularly preferred organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine.
• Crystallizations may produce a solvate of the compounds described herein.
• Embodiments of the present invention include all solvates of the described compounds.
• the term "solvate" refers to an aggregate that comprises one or more molecules of a compound of the invention with one or more molecules of solvent.
• the solvent may be water, in which case the solvate may be a hydrate.
• the solvent may be an organic solvent.
• the compounds of the present invention may exist as a hydrate, including a monohydrate, dihydrate, hemihydrate, sesquihydrate, trihydrate, tetrahydrate and the like, as well as the corresponding solvated forms.
• the compounds of the invention may be true solvates, while in other cases the compounds of the invention may merely retain adventitious water or another solvent or be a mixture of water plus some adventitious solvent.
• Embodiments of the compounds of the invention may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids.
• Embodiments of the present invention are meant to include all such possible isomers, as well as their racemic and optically pure forms.
• Optically active (+) and (-), (R)- and (5)-, or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and fractional crystallization.
• Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC).
• HPLC high pressure liquid chromatography
• stereoisomer refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable.
• the present invention contemplates various stereoisomers and mixtures thereof and includes “enantiomers”, which refers to two stereoisomers whose molecules are nonsuperimposeable mirror images of one another.
• a “tautomer” refers to a proton shift from one atom of a molecule to another atom of the same molecule.
• the present invention includes tautomers of any said compounds.
• Various tautomeric forms of the compounds are easily derivable by those of ordinary skill in the art.
• embodiments of the present invention are directed to dimers and higher polymers of fluorescent and/or colored moieties.
• the fluorescent and or colored moieties are linked by one or more rigid linkers (i.e., moiety "A").
• linker helps to maintain sufficient spatial distance between the fluorescent and/or colored moieties such that intramolecular quenching is reduced or eliminated, thus resulting in a dye compound having a high molar "brightness" (e.g., high fluorescence emission).
• the compounds have the following structure (A):
• L is a linker with sufficient rigidity to maintain spatial separation between one or more (e.g., each) M group so that intramolecular quenching is reduced or eliminated
• R , R R V, L , V and n are as defined for structure (I).
• A is, at each occurrence, independently a moiety comprising one or more, fused, carbocyclic or heterocyclic ring system
• M is, at each occurrence, independently a moiety comprising two or more carbon-carbon double bonds and at least one degree of conjugation
• L 1 is at each occurrence, independently either: i) an optional alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, heteroalkynylene or heteroatomic linker; or ii) a linker comprising a functional group capable of formation by reaction of two complementary reactive groups;
• L 2 , L 3 , L 4 and L 5 are, at each occurrence, independently an optional alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, heteroalkynylene linker or heteroatomic linker;
• R 1 is, at each occurrence, independently H, alkyl or alkoxy;
• R 2 and R 3 are each independently H, OH, SH, alkyl, alkoxy, alkylether,
• R a is O or S
• R is OH, SH, O " , S " , OR d or SR d
• R c is OH, SH, O " , S " , OR d , SR d , alkyl, alkoxy, alkylether , alkoxyalkylether, phosphate, thiophosphate
• R d is a counter ion
• R 4 is, at each occurrence, independently OH, SH, O “ , S " , OR d or SR d ;
• R 5 is, at each occurrence, independently oxo, thioxo or absent;
• Q is, at each occurrence, independently a moiety comprising a reactive group capable of forming a covalent bond with an analyte molecule, a solid support or a complementary reactive group Q';
• n is, at each occurrence, independently an integer of zero or greater, provided that at least one occurrence of m is an integer of one or greater;
• n is an integer of one or greater.
• the various linkers and substituents e.g., M, A, Q, R 1 , R 2 , R 3 , R c L 1 , L 2 , L 3 , L 4 and L 5 ) in the compound of structure (I) are optionally substituted with one more substituent.
• the optional substituent is selected to optimize the water solubility or other property of the compound of structure (I).
• A is at each occurrence, independently a moiety comprising one or more, fused, bicyclic or tricyclic, aryl or heteroaryl ring system.
• A is, at each occurrence, independently a fused, carbocyclic or heterocyclic ring system having one of the following structures:
• L 6 is a direct bond or a linker.
• A at each occurrence, independently has of the following structures:
• the optional linker L 1 can be used as a point of attachment of the M moiety to the remainder of the compound.
• a synthetic precursor to the compound of structure (I) is prepared, and the M moiety is attached to the synthetic precursor using any number of facile methods known in the art, for example methods referred to as "click chemistry.”
• click chemistry any reaction which is rapid and substantially irreversible can be used to attach M to the synthetic precursor to form a compound of structure (I).
• Exemplary reactions include the copper catalyzed reaction of an azide and alkyne to form a triazole (Huisgen 1, 3-dipolar cycloaddition), reaction of a diene and dienophile (Diels-Alder), strain-promoted alkyne-nitrone cycloaddition, reaction of a strained alkene with an azide, tetrazine or tetrazole, alkene and azide [3+2] cycloaddition, alkene and tetrazine inverse-demand Diels-Alder, alkene and tetrazole photoreaction and various displacement reactions, such as displacement of a leaving group by nucleophilic attack on an electrophilic atom.
• the reaction to form L 1 may be performed in an aqueous environment.
• L 1 is at each occurrence a linker comprising a functional group capable of formation by reaction of two complementary reactive groups, for example a functional group which is the product of one of the foregoing "click" reactions.
• the functional group can be formed by reaction of an aldehyde, oxime, hydrazone, alkyne, amine, azide, acylazide, acylhalide, nitrile, nitrone, sulfhydryl, disulfide, sulfonyl halide, isothiocyanate, imidoester, activated ester, ketone, ⁇ , ⁇ -unsaturated carbonyl, alkene, maleimide, a-haloimide, epoxide, aziridine, tetrazine, tetrazole, phosphine, biotin or thiirane functional group with a complementary reactive group.
• the functional group can be formed by reaction of an alkyne and an azide.
• the functional group comprises an alkene, ester, amide, thioester, disulfide, carbocyclic, heterocyclic or heteroaryl group.
• L 1 is a linker comprising a triazolyl functional group.
• ⁇ ⁇ has the following structure:
• L a and L are each independently optional linkers.
• L ⁇ M has the following structure:
• L a and L are each independently optional linkers.
• L la or L lb is absent. In other embodiments, L la or L lb , or both, is present.
• L la and L lb when present, are each independently alkylene or heteroalkylene.
• L la and L lb when present, independently have one of the following structures:
• L 1 is at each occurrence, independently an optional alkylene or heteroalkylene linker.
• L 2 , L 3 , L 4 and L 5 are, at each occurrence, independently Ci-C 6 alkylene, C2-C 6 alkenylene or C2-C 6 alkynylene.
• the compound has the following structure (IA):
• x 6 are, at each occurrence, independently an integer from 0 to 6.
• x 3 and x 4 are both 2 at each occurrence.
• x 1 , x 2 , x 5 and x 6 are each 1 at each occurrence.
• L 1 at each occurrence, independently comprises a triazolyl functional group.
• L 1 at each occurrence, independently an optional alkylene or heteroalkylene linker.
• R 4 is, at each occurrence, independently OH, O " or OR d . It is understood that "OR d “ and “SR d “ are intended to refer to O " and S " associated with a cation.
• the disodium salt of a phosphate group may be represented as:
• R a sodium (Na + ).
• R 5 is, at each occurrence, oxo.
• R 1 is
• R 2 and R 3 are each independently OH or
• Q is, at each occurrence, independently a moiety comprising a reactive group capable of forming a covalent bond with an analyte molecule or a solid support.
• Q is, at each occurrence, independently a moiety comprising a reactive group capable of forming a covalent bond with a complementary reactive group Q'.
• Q' is present on a further compound of structure (I) (e.g., in the R 2 or R 3 position), and Q and Q' comprise complementary reactive groups such that reaction of the compound of structure (I) and the further compound of structure (I) results in covalently bound dimer of the compound of structure (I).
• Multimer compounds of structure (I) can also be prepared in an analogous manner and are included within the scope of embodiments of the invention.
• the type of Q group and connectivity of the Q group to the remainder of the compound of structure (I) is not limited, provided that Q comprises a moiety having appropriate reactivity for forming the desired bond.
• the Q is a moiety which is not susceptible to hydrolysis under aqueous conditions, but is sufficiently reactive to form a bond with a corresponding group on an analyte molecule or solid support (e.g., an amine, azide or alkyne).
• analyte molecule or solid support e.g., an amine, azide or alkyne
• Certain embodiments of compounds of structure (I) comprises Q groups commonly employed in the field of bioconjugation. For example in some
• Q comprises a nucleophilic reactive group, an electrophilic reactive group or a cycloaddition reactive group.
• Q comprises a sulfhydryl, disulfide, activated ester, isothiocyanate, azide, alkyne, alkene, diene, dienophile, acid halide, sulfonyl halide, phosphine, a-haloamide, biotin, amino or maleimide functional group.
• the activated ester is an N- succinimide ester, imidoester or polyflourophenyl ester.
• the alkyne is an alkyl azide or acyl azide.
• the SH moiety will tend to form disulfide bonds with another sulfhydryl group on another compound of structure (I). Accordingly, some embodiments include compounds of structure (I), which are in the form of disulfide dimers, the disulfide bond being derived from SH Q groups.
• the other of R 2 or R 3 is a linker comprising a covalent bond to an analyte molecule or a linker comprising a covalent bond to a solid support.
• the analyte molecule is a nucleic acid, amino acid or a polymer thereof.
• the analyte molecule is an enzyme, receptor, receptor ligand, antibody, glycoprotein, aptamer or prion.
• the solid support is a polymeric bead or nonpolymeric bead.
• m is another variable that can be selected based on the desired fluorescence and/or color intensity.
• m is, at each occurrence, independently an integer of 2 or more.
• m is, at each occurrence, independently an integer from 1 to 10, 3 to 10 or 3 to 6.
• m is, at each occurrence, independently an integer from 1 to 5, for example 1, 2, 3, 4 or 5.
• m is, at each occurrence, independently an integer from 5 to 10, for example 5, 6, 7, 8, 9 or 10.
• n is an integer from 1 to 100. In other embodiments, n is an integer from 1 to 10. In some embodiments, n is 1.
• M is selected based on the desired optical properties, for example based on a desired color and/or fluorescence emission wavelength.
• M is the same at each occurrence; however, it is important to note that each occurrence of M need not be an identical M, and certain embodiments include compounds wherein M is not the same at each occurrence.
• each M is not the same and the different M moieties are selected to have absorbance and/or emissions for use in fluorescence resonance energy transfer (FRET) methods.
• FRET fluorescence resonance energy transfer
• the different M moieties are selected such that absorbance of radiation at one wavelength causes emission of radiation at a different wavelength by a FRET mechanism.
• Exemplary M moieties can be appropriately selected by one of ordinary skill in the art based on the desired end use.
• Exemplary M moieties for FRET methods include fluorescein and 5-TAMRA (5-carboxytetramethylrhodamine, succinimidyl ester) dyes.
• M may be attached to the remainder of the molecule from any position (i.e., atom) on M.
• position i.e., atom
• M may be attached to the remainder of molecule from any position (i.e., atom) on M.
• One of skill in the art will recognize means for attaching M to the remainder of molecule. Exemplary methods include the "click" reactions described herein.
• M moieties which are useful in various embodiments of the invention include, but are not limited to: Xanthene derivatives (e.g., fluorescein, rhodamine, Oregon green, eosin or Texas red); Cyanine derivatives (e.g., cyanine,
• CyTRAK Orange Pyrene derivatives such as cascade blue; Oxazine derivatives (e.g., Nile red, Nile blue, cresyl violet, oxazine 170); Acridine derivatives (e.g., proflavin, acridine orange, acridine yellow); Arylmethine derivatives: auramine, crystal violet, malachite green; and Tetrapyrrole derivatives (e.g., porphin, phthalocyanine or bilirubin).
• Oxazine derivatives e.g., Nile red, Nile blue, cresyl violet, oxazine 170
• Acridine derivatives e.g., proflavin, acridine orange, acridine yellow
• Arylmethine derivatives auramine, crystal violet, malachite green
• Tetrapyrrole derivatives e.g., porphin, phthalocyanine or bilirubin
• M moieties include: Cyanine dyes, xanthate dyes (e.g., Hex, Vic, Nedd, Joe or Tet); Yakima yellow; Redmond red; tamra; texas red and alexa fluor® dyes.
• M comprises three or more aryl or heteroaryl rings, or combinations thereof, for example four or more aryl or heteroaryl rings, or combinations thereof, or even five or more aryl or heteroaryl rings, or combinations thereof.
• M comprises six aryl or heteroaryl rings, or combinations thereof.
• the rings are fused.
• M comprises three or more fused rings, four or more fused rings, five or more fused rings, or even six or more fused rings.
• M is cyclic.
• M is carbocyclic.
• M is heterocyclic.
• M at each occurrence, independently comprises an aryl moiety.
• the aryl moiety is multicyclic.
• the aryl moiety is a fused-multicyclic aryl moiety, for example which may comprise at least 3, at least 4, or even more than 4 aryl rings.
• M at each occurrence, independently comprises at least one heteroatom.
• the heteroatom is nitrogen, oxygen or sulfur.
• M at each occurrence, independently comprises at least one substituent.
• the substituent is a fluoro, chloro, bromo, iodo, amino, alkylamino, arylamino, hydroxy, sulfhydryl, alkoxy, aryloxy, phenyl, aryl, methyl, ethyl, propyl, butyl, isopropyl, t-butyl, carboxy, sulfonate, amide, or formyl group.
• M at each occurrence, independently is a dimethylaminostilbene, quinacridone, fluorophenyl- dimethyl-BODIPY, his-fluorophenyl-BODIPY, acridine, terrylene, sexiphenyl, porphyrin, benzopyrene, (fluorophenyl-dimethyl-difluorobora-diaza-indacene)phenyl, (bis-fluorophenyl-difluorobora-diaza-indacene)phenyl, quaterphenyl, bi-benzothiazole, ter-benzothiazole, bi-naphthyl, bi-anthracyl, squaraine, squarylium, 9, 10- ethynyl anthracene or ter-naphthyl moiety.
• M is, at each occurrence
• M is, at each occurrence, independently a coumarin dye, resorufin dye, dipyrrometheneboron difluoride dye, ruthenium bipyridyl dye, energy transfer dye, thiazole orange dye, polymethine or N-aryl-l,8-naphthalimide dye.
• M at each occurrence is the same. In other embodiments, each M is different. In still more embodiments, one or more M is the same and one or more M is different.
• M is pyrene, perylene, perylene monoimide or 6- FAM or derivative thereof. In some other embodiments, M has one of the following structures:
• the compound is a compound selected from Table 2: Table 2.
• F, E and Y refer to fluorescein, perylene and pyrene moieties, respectively, and have the following structures:
• the presently disclosed dye compounds are "tunable," meaning that by proper selection of the variables in any of the foregoing compounds, one of skill in the art can arrive at a compound having a desired and/or predetermined molar fluorescence (molar brightness).
• the tunability of the compounds allows the user to easily arrive at compounds having the desired fluorescence and/or color for use in a particular assay or for identifying a specific analyte of interest.
• all variables may have an effect on the molar fluorescence of the compounds, proper selection of M, A, m and n is believed to play an important role in the molar fluorescence of the compounds.
• a method for obtaining a compound having a desired molar fluorescence comprising selecting an M moiety having a known fluorescence, preparing a compound of structure (I) comprising the M moiety, and selecting the appropriate variables for A, m and n to arrive at the desired molar fluorescence.
• Molar fluorescence in certain embodiments can be expressed in terms of the fold increase or decrease relative to the fluorescence emission of the parent fluorophore (e.g., monomer).
• the molar fluorescence of the present compounds is l . lx, 1.5x, 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x lOx or even higher relative to the parent fluorophore.
• Various embodiments include preparing compounds having the desired fold increase in fluorescence relative to the parent fluorophore by proper selection of A, m and n.
• compositions comprising any of the foregoing compounds and one or more analyte molecules (e.g., biomolecules) are provided in various other portions of the foregoing compounds and one or more analyte molecules (e.g., biomolecules) are provided in various other portions of the foregoing compounds and one or more analyte molecules (e.g., biomolecules) are provided in various other portions of the foregoing compounds and one or more analyte molecules (e.g., biomolecules) are provided in various other analyte molecules (e.g., biomolecules) are provided in various other portions of the fore molecules and one or more analyte molecules (e.g., biomolecules) are provided in various other organote molecules (e.g., biomolecules) are provided in various other organote molecules (e.g., biomolecules)
• compositions in analytical methods for detection of the one or more analyte molecules are also provided.
• the compounds are useful in various analytical methods.
• R 2 is a linker comprising a covalent linkage to an analyte molecule, such as a biomolecule.
• a linker comprising a covalent linkage to an analyte molecule, such as a biomolecule.
• a biomolecule such as a biomolecule.
• a nucleic acid, amino acid or a polymer thereof e.g., polynucleotide or polypeptide.
• the biomolecule is an enzyme, receptor, receptor ligand, antibody, glycoprotein, aptamer or prion.
• R 2 is a linker comprising a covalent linkage to a solid support such as a microparticle.
• a solid support such as a microparticle.
• the microparticle is a polymeric bead or nonpolymeric bead.
• said optical response is a fluorescent response.
• said sample comprises cells, and some embodiments further comprise observing said cells by flow cytometry.
• the method further comprises distinguishing the fluorescence response from that of a second fluorophore having detectably different optical properties.
• the disclosure provides a method for visually detecting an analyte molecule, such as a biomolecule, comprising:
• the analyte molecule is a nucleic acid, amino acid or a polymer thereof (e.g., polynucleotide or polypeptide). In still more embodiments, the analyte molecule is an enzyme, receptor, receptor ligand, antibody, glycoprotein, aptamer or prion.
• a method for visually detecting an analyte molecule, such as a biomolecule comprising:
• a method for visually detecting an analyte molecule comprising:
• the compounds of structure (I) can be used in various for analysis of cells. For example, by use of flow cytometry, the compounds can be used to discriminate between live and dead cells, evaluate the health of cells (e.g., necrosis vs. early apoptitic vs. late apoptitic vs. live cell), tracking ploidy and mitosis during the cell cycle and determining various states of cell proliferation. While not wishing to be bound by theory, it is believed that embodiments of the compounds of structure (I) preferentially bind to postively charged moieties.
• the compounds may be used in methods for determining the presence of non-intact cells, for example nectrotic cells.
• the presence of nectrotic cells can be determined by admixing a sample containing cells with a compound of structure (I) and analyzing the mixture by flow cytometry.
• the compound of structure (I) binds to nectrotic cells, and thus there presence is detectable under flow cytometry conditions.
• embodiments of the staining methods of employing compounds of structure (I) do not require a protein-free incubation buffer, and thus the methods are more efficient to perform than related known methods.
• the compounds can be used in related methods for determing the presence of positively charged moieties in intact or non- intact cells, apoptitic bodies, depolarized membranes and/or permealized membranes.
• embodiments of the compounds of structure (I) find utility in various disciplines and methods, including but not limited to: imaging in endoscopy procedures for identification of cancerous and other tissues; identification of necrotic tissue by preferential binding of the compounds to dead cells; single-cell and/or single molecule analytical methods, for example detection of polynucleotides with little or no amplification; cancer imaging, for example by conjugating a compound of structure (I) to an antibody or sugar or other moiety that preferentially binds cancer cells; imaging in surgical procedures; binding of histones for identification of various diseases; drug delivery, for example by replacing the M moiety in a compound of structure (I) with an active drug moiety; and/or contrast agents in dental work and other procedures, for example by preferential binding of the compound of structure (I) to various flora and/or organisms.
• any embodiment of the compounds of structure (I), as set forth above, and any specific choice set forth herein for a R 1 , R 2 , R 3 , R 4 , R 5 , L 1 , L 2 , L 3 , L 4 , L 5 , A, M, m and/or n variable in the compounds of structure (I), as set forth above, may be independently combined with other embodiments and/or variables of the compounds of structure (I) to form embodiments of the inventions not specifically set forth above.
• Suitable protecting groups include hydroxy, amino, mercapto and carboxylic acid.
• Suitable protecting groups for hydroxy include trialkylsilyl or diarylalkylsilyl (for example, t-butyldimethylsilyl, t-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl, and the like.
• Suitable protecting groups for amino, amidino and guanidino include t-butoxycarbonyl, benzyloxycarbonyl, and the like.
• Suitable protecting groups for mercapto include -C(0)-R" (where R" is alkyl, aryl or arylalkyl), /?-methoxybenzyl, trityl and the like.
• Suitable protecting groups for carboxylic acid include alkyl, aryl or arylalkyl esters.
• Protecting groups may be added or removed in accordance with standard techniques, which are known to one skilled in the art and as described herein. The use of protecting groups is described in detail in Green, T.W. and P.G.M. Wutz, Protective Groups in Organic Synthesis (1999), 3rd Ed., Wiley.
• Reaction Scheme I illustrates an exemplary method for preparing an intermediate useful for preparation of compounds of structure (I), where R 1 , L 2 , L 3 and M are as defined above, R 2 and R 3 are as defined above or are protected variants thereof and L is an optional linker.
• compounds of structure a can be purchased or prepared by methods well-known to those of ordinary skill in the art.
• Reaction of a with M-X, where x is a halogen such as bromo under Suzuki coupling conditions known in the art results in compounds of structure b.
• Compounds of structure b can be used for preparation of compounds of structure (I) as described below.
• Reaction Scheme II illustrates an alternative method for preparation of intermediates useful for preparation of compounds of structure (I).
• G' may be pendant to M or a part of the structural backbone of M.
• G may be any number of functional groups described herein, such as alkyne.
• the compound of structure (I) may be prepared from one of structures b or d by reaction under well-known automated DNA synthesis conditions with a phosphoramidite compound having the following structure (e):
• A is as defined herein and each L is independently an optional linker.
• DNA synthesis methods are well-known in the art. Briefly, two alcohol groups, for example R 2 and R 3 in intermediates b or d above, are functionalized with a dimethoxytrityl (DMT) group and a 2-cyanoethyl-N,N-diisopropylamino
• DMT dimethoxytrityl
• the phosphoramidite group is coupled to an alcohol group, typically in the presence of an activator such as tetrazole, followed by oxidation of the phosphorous atom with iodine.
• the dimethoxytrityl group can be removed with acid (e.g., chloroacetic acid) to expose the free alcohol, which can be reacted with a phosphoramidite group.
• the 2-cyanoethyl group can be removed after oligomerization by treatment with aqueous ammonia.
• Preparation of the phosphoramidites used in the oligomerization methods is also well-known in the art.
• a primary alcohol e.g., R 3
• a secondary alcohol e.g., R 2
• R 3 a primary alcohol
• R 2 a secondary alcohol
• R 2 is then functionalized as a phosphoramidite by reaction with an appropriate reagent such as 2-cyanoethyl ⁇ , ⁇ -dissopropylchlorophosphoramidite.
• compounds useful for preparation of the compound of structure (I) are provided.
• the compounds can be prepared above in monomer, dimer and/or oligomeric form and then the M moiety covalently attached to the compound via any number of synthetic methodologies (e.g., the "click” reactions described above) to form a compound of structure (I).
• a compound is provided having the following structure (II):
• A is, at each occurrence, independently a moiety comprising one or more, fused, carbocyclic or heterocyclic ring system;
• G is, at each occurrence, independently a moiety comprising a reactive group capable of forming a covalent bond with a complementary reactive group;
• L la , L 2 , L 3 , L 4 and L 5 are, at each occurrence, independently an optional alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, heteroalkynylene or heteroatomic linker;
• R 1 is, at each occurrence, independently H, alkyl or alkoxy
• R d is a counter ion
• R 4 is, at each occurrence, independently OH, SH, O “ , S " , OR d or SR d ;
• R 5 is, at each occurrence, independently oxo, thioxo or absent;
• Q is, at each occurrence, independently a moiety comprising a reactive group capable of forming a covalent bond with an analyte molecule, a solid support or a complementary reactive group Q';
• n is, at each occurrence, independently an integer of zero or greater, provided that at least one occurrence of m is an integer of one or greater;
• n is an integer of one or greater.
• the G moiety in the compound of structure (II) can be selected from any moiety comprising a group having the appropriate reactivity group for forming a covalent bond with a complementary group on an M moiety.
• the G moiety can be selected from any of the Q moieties described herein, including those specific examples provided in Table 1.
• G comprises, at each occurrence, independently a moiety suitable for reactions including: the copper catalyzed reaction of an azide and alkyne to form a triazole (Huisgen 1, 3-dipolar cycloaddition), reaction of a diene and dienophile (Di els- Alder), strain-promoted alkyne-nitrone cycloaddition, reaction of a strained alkene with an azide, tetrazine or tetrazole, alkene and azide [3+2] cycloaddition, alkene and tetrazine inverse-demand Diels-Alder, alkene and tetrazole photoreaction and various displacement reactions, such as displacement of a leaving group by nucleophilic attack on an electrophilic atom.
• G is, at each occurrence, independently a moiety comprising an aldehyde, oxime, hydrazone, alkyne, amine, azide, acylazide, acylhalide, nitrile, nitrone, sulfhydryl, disulfide, sulfonyl halide, isothiocyanate, imidoester, activated ester, ketone, ⁇ , ⁇ -unsaturated carbonyl, alkene, maleimide, a-haloimide, epoxide, aziridine, tetrazine, tetrazole, phosphine, biotin or thiirane functional group.
• G comprises, at each occurrence, independently an alkyne or an azide group.
• G comprises, at each occurrence, independently a reactive group capable of forming a functional group comprising an alkene, ester, amide, thioester, disulfide, carbocyclic, heterocyclic or heteroaryl group, upon reaction with the complementary reactive group.
• the heteroaryl is triazolyl.
• L 2 , L 3 , L 4 and L 5 are, at each occurrence, independently Ci-C 6 alkylene, C 2 -C 6 alkenylene or C 2 -C 6 alkynylene.
• the compound has the following structure (IIA):
• each L la is absent. In other embodiments, each L la is present, for example L la is, at each occurrence, independently heteroalkylene.
• G is, at each occurrence, independently ⁇ or ⁇ 3 .
• x 3 and x 4 are both 2 at each occurrence. In other embodiments, x 1 , x 2 , x 5 and x 6 are each 1 at each occurrence.
• A is at each occurrence, independently a moiety comprising one or more, fused, aryl or heteroaryl ring system. In different embodiments, A is at each occurrence,
• A is, at each occurrence, independently a fused, carbocyclic or heterocyclic ring system having one of the following structures:
• a 1 , a 2 and a 3 are, at each occurrence, independently a 5, 6 or 7-membered carbocyclic or heterocyclic ring;
• L 6 is a direct bond or a linker.
• R 4 is, at each occurrence, independently OH, O or OR d
• R 5 is, at each occurrence, oxo.
• R 1 is H.
• Q is, at each occurrence, independently a moiety comprising a reactive group capable of forming a covalent bond with an analyte molecule or a solid support.
• Q is, at each occurrence, independently a moiety comprising a reactive group capable of forming a covalent bond with a complementary reactive group Q'.
• Q' is present on a further compound of structure (II) or (Ila) (e.g., in the R 2 or R 3 position), and Q and Q' comprise complementary reactive groups such that reaction of the compound of structure (II) or (Ila) and the further compound of structure (II) or (Ila) results in covalently bound dimer of the compound of structure (II) or (Ila).
• Multimer compounds of structure (II) of (Ila) can also be prepared in an analogous manner and are included within the scope of embodiments of the invention.
• the type of Q group and connectivity of the Q group to the remainder of the compound of structure (II) or (Ila) is not limited, provided that Q comprises a moiety having appropriate reactivity for forming the desired bond.
• the Q is a moiety which is not susceptible to hydrolysis under aqueous conditions, but is sufficiently reactive to form a bond with a corresponding group on an analyte molecule or solid support (e.g., an amine, azide or alkyne).
• Q comprises Q groups commonly employed in the field of bioconjugation.
• Q comprises a nucleophilic reactive group, an electrophilic reactive group or a cycloaddition reactive group.
• Q comprises a sulfhydryl, disulfide, activated ester, isothiocyanate, azide, alkyne, alkene, diene, dienophile, acid halide, sulfonyl halide, phosphine, a-haloamide, biotin, amino or maleimide functional group.
• the activated ester is an N- succinimide ester, imidoester or polyflourophenyl ester.
• the alkyne is an alkyl azide or acyl azide.
• the SH moiety will tend to form disulfide bonds with another sulfhydryl group on another compound of structure (II) or (Ila). Accordingly, some embodiments include compounds of structure (II) or (Ila), which are in the form of disulfide dimers, the disulfide bond being derived from SH Q groups.
• the analyte molecule is a nucleic acid, amino acid or a polymer thereof.
• the analyte molecule is an enzyme, receptor, receptor ligand, antibody, glycoprotein, aptamer or prion.
• the solid support is a polymeric bead or nonpolymeric bead.
• n is an integer from 1 to 100.
• n is an integer from 1 to 10.
• the compound of structure (II) is selected from Table 3.
• the compounds of structure (II) or (Ila) can be used in various methods, for example in embodiments is provided a method for labeling an analyte molecule, the method comprising:
• M is a moiety comprising two or more carbon-carbon double bonds and at least one degree of conjugation
• L lb is an optional alkylene, heteroalkylene or heteroatomic linker; and G' is a reactive group complementary to G.
• a different embodiment is a method for labeling an analyte molecule, the method comprising:
• step (b) reacting the product of step (A) with the analyte molecule, thereby forming a conjugate of the product of step (A) and the analyte molecule,
• M is a moiety comprising two or more carbon-carbon double bonds and at least one degree of conjugation
• L lb is an optional alkylene, heteroalkylene or heteroatomic linker; and G' is a reactive group complementary to G.
• the compound of structure (II) are useful for preparation of compounds of structure (I). Accordingly, in one embodiment is provided a method for preparing a compound of structure (I), the method comprising admixing a compound of structure (II) with a compound of formula M-L lb -G', thereby forming at least one covalent bond by reaction of G and G', wherein:
• M is a moiety comprising two or more carbon-carbon double bonds and at least one degree of conjugation
• L lb is an optional alkylene, heteroalkylene or heteroatomic linker
• G' is a reactive group complementary to G.
• Phosphoramidites and precursor molecules were also analyzed using a Waters Acquity UHPLC system with a 2.1mm x 50mm Acquity BEH-C18 column held at 45°C, employing an acetonitrile/water mobile phase gradient.
• Molecular weights for monomer intermediates were obtained using tropylium cation infusion enhanced ionization on a Waters/Micromass Quattro micro MS/MS system (in MS only mode). Excitation and emission profiles experiments were recorded on a Cary Eclipse spectra photometer.
• oligonucleotide dyes were synthesized on an ABI 394 DNA synthesizer using standard protocols for the phosphoramidite based coupling approach.
• the chain assembly cycle for the synthesis of oligonucleotide phosphoramidates was the following: (i) detritylation, 3% trichloroacetic acid in dichloromethane, 1 min; (ii) coupling, 0.1 M phosphoramidite and 0.45 M tetrazole in acetonitrile, 10 min; (iii) capping, 0.5 M acetic anhydride in THF/lutidine, 1/1, v/v 15 s; (iv) oxidation, 0.1 M iodine in THF/pyri dine/water, 10/10/1, v/v/v, 30 s.
• Oligomer dyes were synthesized on an Applied Biosy stems 394
• Dyes were synthesized directly on CPG beads or on polystyrene solid support. The dyes were synthesized in the 3' to 5' direction by standard solid phase DNA methods. Coupling methods employed standard ⁇ -cyanoethyl phosphoramidite chemistry conditions. Different number of repeating units were incorporated by repeating the synthesis cycle the desired number of times with an appropriate phosphoramidite.
• the monomethoxytrityl (MMT) group or dimthoxytrityl (DMT) group was removed with dichloroacetic acid in dichloromethane or dichloroacetic acid in toluene.
• the dyes were cleaved from the solid support and deprotected as follows: A 1 mL micropipettor was used to add 450 ⁇ . of concentrated H 4 OH to -25 mg of reacted CPG solid support in a 1.5 mL Eppendorf tube. The slurry was mixed briefly using a Vortex mixer and allowed to settle before placing (open) on a 55°C heating block until gas formation (and bubbling) started to diminish, at which point the tube was tightly closed. Heat treatment was for 2 hours (+/- 15 minutes) and tubes were then removed to cool to room temperature.
• the tube and its contents were spun in a centrifuge at its maximum speed (13400 rpm) for 1 minute, and then the supernatant was removed with a glass pipette and placed into a second, labeled, 1.5mL Eppendorf tube, taking care not to include the support.
• the support was washed and spun-down 2x with ⁇ 150 ⁇ of acetonitrile to help maximize dye removal, and the washings were carefully removed from support and added to the labeled secondary tubes. Clarified supernatant was dried completely in a CentriVap concentrator at 40°C to remove H 4 OH.
• a sample was taken from a concentrated stock using a micropipettor and diluted appropriately in 0. IX PBS (lOx to lOOx) to be within linear range of the NanoDrop UV-vis spetrophotomer (Thermo Scientific).
• IX PBS lOx to lOOx
• a blank measurement was performed on the NanoDrop using 0.1X PBS, and then the absorbance of the diluted dye sequence at an appropriate wavelength was recorded.
• Extinction coefficients were determined by the total number of fluors (M moieties) in the dye construct, using 75,000 M “1 cm “1 for each fluorescein (F; read at 494nm); 34,500 for each pyrene (Y; read at 343nm); and 40,000 for each perylene (E; read at 440nm) present in the sequence. Spacers and linkers are presumed to have no effect on ⁇ .
• the dye stock was diluted in the NaP0 4 (0.1 M at pH 7.5) and NaC0 3 (0.1 M at pH 9.0) buffers to make solutions of 2 ⁇ (or 5 ⁇ , whatever works with the linear range of the instrument) at a final volume of -3.5 mL. These solutions were scanned by UV/Vis, and then used them to make a second dilution in the appropriate buffer for reading on the fluorimeter, in the range of 10 - 50nM. The necessary concentration will vary depending upon the identity of the M moiety.
• the absorbance of the 2 ⁇ sample was determined, scanning from 300nm to 700nm. Scan speed was set to medium.

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Immunology (AREA)
• Engineering & Computer Science (AREA)
• Molecular Biology (AREA)
• General Health & Medical Sciences (AREA)
• Biochemistry (AREA)
• Physics & Mathematics (AREA)
• Analytical Chemistry (AREA)
• Biomedical Technology (AREA)
• Pathology (AREA)
• General Physics & Mathematics (AREA)
• Hematology (AREA)
• Urology & Nephrology (AREA)
• Optics & Photonics (AREA)
• Biotechnology (AREA)
• Medicinal Chemistry (AREA)
• Food Science & Technology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Cell Biology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Microbiology (AREA)
• Materials Engineering (AREA)
• Plural Heterocyclic Compounds (AREA)
• Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
• Investigating Or Analysing Biological Materials (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (1)

Family

ID=58609994

Family Applications (1)

Country Status (6)

Cited By (25)

Families Citing this family (3)

Citations (1)

Family Cites Families (138)

• 2017
  • 2017-03-31 US US16/090,560 patent/US11434377B2/en active Active
  • 2017-03-31 EP EP17719074.1A patent/EP3436528B1/en active Active
  • 2017-03-31 KR KR1020187031703A patent/KR102525252B1/ko active Active
  • 2017-03-31 CN CN201780019799.0A patent/CN109415574B/zh active Active
  • 2017-03-31 JP JP2018549448A patent/JP7145079B2/ja active Active
  • 2017-03-31 WO PCT/US2017/025513 patent/WO2017173348A1/en not_active Ceased

Patent Citations (1)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events